Minerva Neurosciences: Complete Response Letter from FDA for NDA for roluperidone for the treatment of negative symptoms in patients with schizophrenia

Minerva Neurosciences, Inc. announced that the FDA has issued a Complete Response Letter (CRL) to the Company's New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia